Cancer-Focused Biotech Co. Prices $60M IPO At Low End
BioXcel Therapeutics Inc., a company using artificial intelligence to develop drugs that fight cancer and neurological disorders, raised $60 million in an initial public offering that priced at the bottom of...To view the full article, register now.
Already a subscriber? Click here to view full article